1. Home
  2. QTWO vs NUVL Comparison

QTWO vs NUVL Comparison

Compare QTWO & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QTWO
  • NUVL
  • Stock Information
  • Founded
  • QTWO 2004
  • NUVL 2017
  • Country
  • QTWO United States
  • NUVL United States
  • Employees
  • QTWO N/A
  • NUVL N/A
  • Industry
  • QTWO Computer Software: Prepackaged Software
  • NUVL Biotechnology: Pharmaceutical Preparations
  • Sector
  • QTWO Technology
  • NUVL Health Care
  • Exchange
  • QTWO Nasdaq
  • NUVL Nasdaq
  • Market Cap
  • QTWO 4.8B
  • NUVL 5.4B
  • IPO Year
  • QTWO 2014
  • NUVL 2021
  • Fundamental
  • Price
  • QTWO $95.02
  • NUVL $85.92
  • Analyst Decision
  • QTWO Buy
  • NUVL Strong Buy
  • Analyst Count
  • QTWO 16
  • NUVL 11
  • Target Price
  • QTWO $95.56
  • NUVL $112.36
  • AVG Volume (30 Days)
  • QTWO 597.5K
  • NUVL 535.6K
  • Earning Date
  • QTWO 02-12-2025
  • NUVL 02-25-2025
  • Dividend Yield
  • QTWO N/A
  • NUVL N/A
  • EPS Growth
  • QTWO N/A
  • NUVL N/A
  • EPS
  • QTWO N/A
  • NUVL N/A
  • Revenue
  • QTWO $675,537,000.00
  • NUVL N/A
  • Revenue This Year
  • QTWO $13.23
  • NUVL N/A
  • Revenue Next Year
  • QTWO $11.35
  • NUVL N/A
  • P/E Ratio
  • QTWO N/A
  • NUVL N/A
  • Revenue Growth
  • QTWO 10.92
  • NUVL N/A
  • 52 Week Low
  • QTWO $40.60
  • NUVL $61.80
  • 52 Week High
  • QTWO $112.82
  • NUVL $113.51
  • Technical
  • Relative Strength Index (RSI)
  • QTWO 45.63
  • NUVL 56.75
  • Support Level
  • QTWO $91.05
  • NUVL $83.71
  • Resistance Level
  • QTWO $100.83
  • NUVL $89.12
  • Average True Range (ATR)
  • QTWO 3.30
  • NUVL 3.27
  • MACD
  • QTWO 0.33
  • NUVL 1.17
  • Stochastic Oscillator
  • QTWO 40.63
  • NUVL 78.60

About QTWO Q2 Holdings Inc.

Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: